The 5 Most Interesting Analyst Questions From Adtalem's Q1 Earnings Call

Adtalem’s first quarter was marked by robust enrollment increases across its core healthcare education segments, fueling a positive market reaction. Management attributed the strong top-line and margin improvement to both sustained demand in nursing and healthcare programs and operational efficiencies in student-facing platforms. CEO Steve Beard credited “seven consecutive quarters of enrollment growth” and highlighted the success of digital initiatives at Walden University, which drove higher student retention and academic performance. Additional enrollment gains at Chamberlain and the return to growth in the Medical and Veterinary segment also underpinned the company’s quarterly performance.

Is now the time to buy ATGE? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Adtalem’s Q1 Earnings Call

• Jack Slevin (Jefferies) asked how Adtalem’s recent outperformance affects its long-term growth targets. CEO Steve Beard noted Investor Day benchmarks remain appropriate but will be recalibrated in future updates.
• Jack Slevin (Jefferies) inquired about potential impacts from proposed federal student loan and accountability reforms. Beard responded that Adtalem’s career-focused, high-return programs are well-positioned and not directly affected by current proposals.
• Jeff Silber (BMO Capital Markets) questioned whether student enrollment decisions were being influenced by legislative uncertainty. Beard reported no observable hesitancy, stating students remain confident in program financing.
• Jeff Silber (BMO Capital Markets) sought clarity on margin declines in the Medical and Veterinary segment. CFO Bob Phelan cited a mix of one-time and structural costs tied to long-term growth investments, with expectations for future margin improvement.
• Steve Pawlak (Baird) requested more detail on Walden’s digital retention tools. Beard explained that predictive analytics now enable targeted interventions, leading to record persistence in key programs.

Catalysts in Upcoming Quarters

Going forward, the StockStory team will monitor (1) the pace of enrollment growth across nursing and healthcare programs, (2) the effectiveness of investments in digital engagement platforms on student retention and outcomes, and (3) the company’s ability to scale program capacity and geographic reach. Additionally, we are watching for regulatory developments and their potential influence on funding and demand.

Adtalem currently trades at $123.05, up from $116.10 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.